Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Drugs like Ozempic have a positive impact on weight loss, though only for a short period, with long-term health implications ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

GLP-1 Drugs and Higher Risk of Fractures In the second ... and any potential side effects from the medication." "Future studies should explore how the amount of weight loss, the duration of ...